Emetic Risk of Single Intravenous Antineoplastic Agents in Adults

Home , Abemaciclib, Acalabrutinib, Alpelisib, Arsenic trioxide, Avapritinib, Belinostat

Minimal Low Moderate High (< 10%) (10%-30%) (30%-90%) (> 90%)

▪ Atezolizumab ▪ Aflibercept ▪ Alemtuzumab ▪ Anthracycline/ ▪ Avelumab ▪ Axicabtagene ciloleucel ▪ Arsenic trioxide cyclophosphamide ▪ Bevacizumab ▪ Belinostat ▪ Azacitidine combination ▪ Bleomycin ▪ Blinatumomab ▪ Bendamustine ▪ Carmustine ▪ Busulfan ▪ Bortezomib ▪ Carboplatin ▪ Cisplatin ▪ Cemiplimab ▪ Brentuximab ▪ Clofarabine ▪ Cyclophosphamide > 1,500 ▪ 2-Chlorodeoxyadenosine ▪ Cabazitaxel ▪ Cyclophosphamide < 1,500 mg/m² ▪ Cladribine ▪ Carfilzomib mg/m² ▪ Dacarbazine ▪ Daratumumab ▪ Catumaxumab ▪ Cytarabine > 1,000 mg/m² ▪ Mechlorethamine ▪ Durvalumab ▪ Cetuximab ▪ Daunorubicin ▪ Streptozocin ▪ Emapalumab ▪ Copanlisib ▪ Daunorubicin and ▪ Fludarabine ▪ Cytarabine ≤ 1,000 mg/m² cytarabine liposome ▪ Ipilimumab ▪ Decitabine ▪ Doxorubicin ▪ Nivolumab ▪ Docetaxel ▪ Epirubicin ▪ Obinutuzumab ▪ Elotuzumab ▪ Idarubicin ▪ Ofatumumab ▪ Enfortumab vedotin-ejfv ▪ Ifosfamide ▪ Pembrolizumab ▪ Eribulin ▪ Irinotecan ▪ Pixantrone ▪ Etoposide ▪ Irinotecan liposomal ▪ Polatuzumab vedotin ▪ Fluorouracil injection ▪ Pralatrexate ▪ Gemcitabine ▪ Oxaliplatin ▪ Ramucirumab ▪ Gemcitabine ozogamicin ▪ Romidepsin ▪ Rituximab ▪ Inotuzumab ozogamicin ▪ Temozolomide* ▪ Trastuzumab ▪ Ixabepilone ▪ Thiotepa† ▪ Vinblastine ▪ Methotrexate ▪ Trabectedin ▪ Vincristine ▪ Mitomycin ▪ Vinorelbine ▪ Mitoxantrone ▪ Moxetumomab pasudotox ▪ Nab-paclitaxel ▪ Necitumumab ▪ Nelarabine ▪ Paclitaxel ▪ Panitumumab ▪ Pegylated liposomal doxorubicin ▪ Pemetrexed ▪ Pertuzumab ▪ Tagraxofusp-erzs ▪ Temsirolimus ▪ Topotecan ▪ Trastuzumab-emtansine ▪ Vinflunine * No direct evidence found for intravenous temozolomide; as all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide. †Classification refers to individual evidence from pediatric trials.

This chart is derived from recommendations in Antiemetics: ASCO Guideline Update. This is a tool based on an ASCO guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

www.asco.org/supportive-care-guidelines ©American Society of Clinical Oncology 2020. All rights reserved. For licensing opportunities, contact [email protected] Emetic Risk of Single Oral Antineoplastic Agents in Adults*

Minimal or Low Moderate or High (< 30%) (> 30%)

▪ 6-Thioguanine ▪ Lenalidomide ▪ Abemaciclib ▪ Acalabrutinib ▪ Lenvatinib ▪ Avapritinib ▪ Afatinib ▪ Lorlatinib ▪ Bosutinib ▪ Alectinib ▪ Melphalan ▪ Cabozantinib ▪ Alpelisib ▪ Methotrexate ▪ Ceritinib ▪ Axatinib ▪ Neratinib ▪ Crizotinib ▪ Bexarotene ▪ Nilotinib ▪ Cyclophosphamide ▪ Brigatinib ▪ Olaparib ▪ Enasidenib ▪ Capecitabine ▪ Osimertinib ▪ Fedratinib ▪ Chlorambucil ▪ Palbociclib ▪ Hexamethylmelamine ▪ Cobimetinib ▪ Panobinostat ▪ Imatinib ▪ Dabrafenib ▪ Pazopanib ▪ Lenvatinib ▪ Dacomitinib ▪ Pexidartinib ▪ Lomustine ▪ Dasatinib ▪ Pomalidomide ▪ Midostaurin ▪ Duvelisib ▪ Ponatinib ▪ Niraparib ▪ Encorafenib ▪ Regorafenib ▪ Procarbazine ▪ Entrectinib ▪ Ruxolitinib ▪ Ribociclib ▪ Erdafitinib ▪ Sonidegib ▪ Rucaparib ▪ Erlotinib ▪ Sorafenib ▪ Selinexor ▪ Estramustine ▪ Sunitinib ▪ TAS-102 (trifluridine- ▪ Etoposide ▪ Talazoparib tipiracil) ▪ Everolimus ▪ Tazemetostat ▪ Temozolomide ▪ Fludarabine ▪ Tegafur-Uracil ▪ Vinorelbine ▪ Gefitinib ▪ Thalidomide ▪ Gilteritinib ▪ Topotecan ▪ Glasdegib ▪ Trametinib ▪ Hydroxyurea ▪ Vandetanib ▪ Ibrutinib ▪ Vemurafenb ▪ Idelalisib ▪ Venetoclax ▪ Ivosidenib ▪ Vismodegib ▪ Ixazomib ▪ Vorinostat ▪ Lapatinib ▪ Zanubrutinib ▪ Larotrectinib *Classified emetic potential of oral agents based on a full course of therapy and not a single dose.

Minimal Low Moderate High (< 10%) (10%-30%) (30%-90%) (> 90%)

▪ Extremities ▪ Brain ▪ Upper Abdomen ▪ Total Body ▪ Breast ▪ Head and Neck ▪ Craniopinal Irradiation ▪ Thorax Irradiation ▪ Pelvis